Publications/Reports

2026

Global position statement supporting a World Health Assembly resolution on steatotic liver disease
Lazarus J, Halpern B, Schwarz P E H, Boudou D, Van Spall H G C, Miller V, Duseja A. Nat Rev Gastroenterol Hepatol. 2026; 10.1038/s41575-026-01201-z

2025

Strengthening hepatitis B virus clinical research in Africa: the need for multistakeholder collaboration, funding, and political will
Leus M, Osakwe C E, Adda D, El-Sayed M, Hicks J, Ibrahim Y, Matthews P C, Ndembi N, Owusu-Ansah T, Spearman C W, Sonderup M W, Ward J, Schaefer R, Miller V. The Lancet Microbe. 2025; 10.1016/j.lanmic.2025.101266

SMART Steps to HBV Cure
Miller V, Terrault N. Hepatology, 82(6). 2025; 10.1097/HEP.0000000000001499

Challenges and opportunities in developing integrated sexual and reproductive health programmes
Mayer K H, Beyrer C, Cohen M S, El-Sadr W M, Grinsztejn B, Head J M, Keuroghlian A S, Miller V, Phanuphak N, Rees H, Reid M, Starrs A, Warren M, Bekker L. The Lancet, Volume 406, Issue 10515. 2025; 10.1016/S0140-6736(25)01246-2

Multisector global collaboration to advance the inclusion of pregnant and lactating people in HIV prevention research
Schaefer R, Lievense B, Day S, Donaldson L, Bekker L, Chigome A, Kumwenda G, Noguchi L, Osakwe C, Miller V, Lyerly A, Chatani-Gada M. AIDS. 2025; 10.1097/QAD.0000000000004257

Do we need a regulatory path for HIV post-exposure prophylaxis?
Miller V, Schaefer R. J Int AIDS. 2025; 10.1002/jia2.26449

Standardising HBV nomenclature: a call to action from the HBV Forum
Wang S, Leus M, Cornberg M, Ghany M, Hwang C, Lim S G, McMahon B, Spearman C W, Miller V. The Lancet Gastroenterology & Hepatology. 2025; 10.1016/S2468-1253(25)00158-X

Multipurpose prevention technologies for the prevention of unintended pregnancy, HIV, and other sexually transmitted infections: regulatory pathways and challenges
Donaldson L, Schaefer R, Alhakimi S, Akulu R, Palanee-Phillips T, Young Holt B, Miller V. Front. Reprod. Health. 2025; 10.3389/frph.2025.1591232

Antiretroviral use for HIV prevention during pregnancy: the need to strengthen regulatory and surveillance systems in Africa
Schaefer R, Donaldson L, Chigome A, Escudeiro dos Santos M, Lamprianou S, Ndembi N, Nwokike JI, Nyambayo P, Palmi V, Renaud F, Gonzalez Tome M, Miller V. Drug Safety. 2025; 10.1007/s40264-024-01494-6

Refractory and Resistant Herpes Simplex Virus Mucocutaneous Infections in Immunocompromised Patients: Literature Review and Proposed Definitions for Use in Clinical Trials
Chemaly R F, Shafat T, Wald A, Kotton C N, Papanicolaou G, Yong M K, Miller V, Komatsu T E, Mullick C, Hodowanec A C, Westman G, Khawaja F, Birkmann A, Ljungman P, HSV Resistance Working Group of the Transplant Associated Viral Infections Forum. Clinical Infectious Diseases. 2025; 10.1093/cid/ciae638

2024

Promising results of HIV prevention trials highlight the benefits of collaboration in global health: The perspective of the Forum HIV Recency Assay Working Group
Schaefer R, Donaldson L, Leus M, Osakwe CE, Chimukangara B, Dalal S, et al. PLOS Glob Public Health. 2024; 10.1371/journal.pgph.0003878

Twenty-five years of addressing cutting-edge scientific, policy, and regulatory issues through collaboration: The Forum for Collaborative Research
Schaefer R, Ayvaz A, Hoffman C, Yann M, Rooney Z, Leus M, Mitra S, Miller V, for the Forum for Collaborative Research. Clinical and Translational Science 2024; 10.1111/cts.70051.

Integrating liver endpoints in clinical trials of cardiovascular and kidney disease
Zannad F, Sanyal AJ, Butler J, Miller V, Harrison SA. Nature Medicine 2024; 10.1038/s41591-024-03223-z.

Chronic Hepatitis B Finite Treatment: similar and different concerns with new drug classes
Peters MG, Yuen MF, Terrault N, Fry J, Lampertico P, Gane E, Hwang C, Stamm LM, Leus M, Maini MK, Mendez P, Lonjon-Domanec I, Berg T, Wang S, Mishra P, Donaldson E, Buchholz S, Miller V, Lenz O. Clin Inf Dis. 2023; 10.1093/cid/ciad506.

Consensus Definitions of Cytomegalovirus (CMV) Infection and Disease in Transplant Patients Including Resistant and Refractory CMV for Use in Clinical Trials: 2024 Update From the Transplant Associated Virus Infections Forum
Ljungman P, Chemaly RF, Khawaya F, Alain S, Avery R, Badshah C, Boeckh M, Fournier M, Hodowanec A, Komatsu T, Limaye AP, Manuel O, Natori Y, Navarro D, Pikis A, Razonable RR, Westman G, Miller V, Griffiths PD, Kotton CN for the CMV Definitions Working Group. Clin Inf Dis. 2024; 10.1093/cid/ciae321.

Recommendations from the Forum for Collaborative Research’s symposium on hepatitis B elimination and universal hepatitis B adult vaccination in the United States.
Leus M, Treat M, Miller V, Reingold A. J Virus Erad. 2024; 10.1016/j.jve.2024.100376.

A Surrogate Endpoint Based Provisional Approval Causal Roadmap
Gilbert PB, Peng J, Han L, Lange T, Lu Y, Nie L, Shih M, Waddy SP, Wiley K, Yann M, Zafari Z, Ghosh D, Follmann D, Juraska M, Díaz I. arXiv 2024; 10.48550/arXiv.2407.06350.

Long-acting HIV Treatments: Study Design, Logistics, and Access
Murdock NA, Alajaji NE, Schaefer R, Boone CA, Campo RE, Dore GJ, Gandhi M, Gorospe JR, Gulick RM, Hodder SL, Liu J, Rhee MS, Rooney JF, Vannappagari V, Wilkin T, Miller V. Open Forum Infectious Diseases. 2024; 10.1093/ofid/ofae337.

2023

Liver biopsy for assessment of suspected drug-induced liver injury in metabolic dysfunction-associated steatohepatitis clinical trials: Expert consensus from the Liver Forum
Palmer M, Kleiner DE, Goodman Z, Brunt E, Avigan M, Regev A, Hayashi P, Lewis J, Mehta R, Harrison S, Siciliano M, McWherter CA, Vuppalanchi R, Behling C, Miller V, Chalasani N, Sanyal A. Aliment Pharmacol Ther. 2024; 10.1111/apt.17762.

Facilitating Next-Generation Pre-Exposure Prophylaxis Clinical Trials Using HIV Recent Infection Assays: A Consensus Statement from the Forum HIV Prevention Trial Design Project
Parkin N, Gao F, Grebe E, Cutrell A, Das M, Donnell D, Duerr A, Glidden DV, Hughes JP, Murray J, Robertson MN, Zinserling J, Lau J, Miller V. Clin Pharmacol Ther. 2022; 10.1002/cpt.2830.

A proposal from the Liver Forum for the management of comorbidities in nonalcoholic steatohepatitis therapeutic trials
Pais R, Cariou B, Noureddin M, Francque S, Schattenberg JM, Abdelmalek MF, Lalazar G, Varma S, Dietrich J, Miller V, Sanyal A, Ratziu V. J Hepatol 2023; 10.1016/j.jhep.2023.03.014.

HDV RNA Assays: Performance characteristics, clinical utility and challenges
Wedermeyer H, Leus M, Battersby TR, Glenn J, Gordien E, Kamili S, Kapoor J, Kessler HH, Lenz O, Luetgehetmann M, Mixson-Hayden T, Simon CO, Thomson M, Westman G, Miller V, Terrault N, Lampertico P. Hepatology 2023; 10.1097/HEP.0000000000000584.

2022

Consensus Definitions of BK Polyomavirus Nephropathy in Renal Transplant Recipients for Clinical Trials
Imlay H, Baum P, Brennan DC, Hanson KE, Hodges MR, Hodowanec AC, Komatsu TE, Ljungman P, Miller V, Natori Y, Nickeleit V, O'Rear J, Pikis A, Randhawa PS, Sawinski D, Singh H K, Westman G, Limaye AP. Clin Inf Dis. 2022; 75(7): 1210-1216.10.1093/cid/ciac071.

Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles
Kidwell KM, Roychoudhury S, Wendelberger B, Scott J, Moroz T, Yin S, Majumder M, Zhong J, Huml RA, Miller V. Orphanet J Rare Dis. 2022; 17(1): 186.10.1186/s13023-022-02342-5.

Immunological biomarker discovery in cure regimens for chronic hepatitis B virus infection
Gehring AJ, Mendez P, Richter K, Ertl H, Donaldson EF, Mishra P, Maini M, Boonstra A, Lauer G, de Creus A, Whitaker K, Martinez SF, Weber J, Gainor E, Miller V. J Hepatol 2022; 10.1016/j.jhep.2022.02.020.

A systematic review of limiting antigen avidity enzyme immunoassay for detection of recent HIV-1 infection to expand supported applications
Lau J, Murdock N, Murray J, Justman J, Parkin N, Miller V. J Virus Erad. 2022; 8(3): 100085.10.1016/j.jve.2022.100085.

Nomenclature of HBV core protein-targeting antivirals
Zoulim F, Zlotnick A, Buchholz S, Donaldson E, Fry J, Gaggar A, Hu J, Kann M, Lenz O, Lin K, Mani N, Nassal M, Delaney W, Wang S, Westman G, Miller V, Janssen HLA. Nat Rev Gastroenterol Hepatol 2022; 19(12): 748-750.10.1038/s41575-022-00700-z.

2021

Association between rectal gonorrhoea and HIV incidence in men who have sex with men: a meta-analysis
Donnell D, Zewdie K, Ratna N, Miller V, Saunders J, Gill O, Delpech V, Mohammed H. Sexually Transmitted Infections 2022; 10.1136/sextrans-2021-055254.

Association Between Seroclearance of Hepatitis B Surface Antigen and Long-term Clinical Outcomes of Patients With Chronic Hepatitis B Virus Infection: Systematic Review and Meta-analysis
Anderson RT, Choi HSJ, Lenz O, Peters MG, Janssen HLA, Mishra P, Donaldson E, Westman G, Buchholz S, Miller V, Hansen BE. Clin Gastroenterol Hepatol 2021; 19(3): 463-472.10.1016/j.cgh.2020.05.041.

The Use of External Controls in FDA Regulatory Decision Making
Jahanshahi M, Gregg K, Davis G, Ndu A, Miller V, Vockley J, Ollivier C, Franolic T, Sakai S. Ther Innov Regul Sci. 2021; 55(5): 1019-1035.10.1007/s43441-021-00302-y.

Commentary title: COVID-19 research, Africa, and global health
Mbichila T, Kumwenda G, Yola N, Karim QA, Tchelidze T, Lau J, Buchholz S, Lehnert R, Molina JM, Mayer K, Miller V. Virus Erad. 2021; 7(1): 100030.10.1016/j.jve.2021.100030.

2020

Standardization of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum
Glass O, Filozof C, Noureddin M, Berner-Hansen M, Schabel E, Omokaro SO, Schattenberg JM, Barradas K, Miller Standardization of Diet, Francque S, Abdelmalek MF. J Hepatol 2020; 73(3): 680-693.10.1016/j.jhep.2020.04.030.

Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations from the Multi-stakeholder Liver Forum
Noureddin M, Chan JL, Barradas K, Dimick-Santos L, Schabel E, Omokaro SO, Anania FA, Myers RP, Miller V, Sanyal AJ, Chalasani N. Gastroenterology 2020; 159(2): 422-427 e421.10.1053/j.gastro.2020.04.039.

2019

Liver safety assessment in clinical trials of new agents for chronic hepatitis B
Fontana RJ, Avigan MI, Janssen HLA, Regev A, Mishra P, Gaggar A, Brown N, Wat C, Mendez P, Anderson RT, Given B, Miller V, Beumont M. J Viral Hepat. 2020; 27(2): 96-109.10.1111/jvh.13223.

Factors to Consider in Development of Drugs for Pediatric Nonalcoholic Fatty Liver Disease
Vos MB, Dimick-Santos L, Mehta R, Omokaro SO, Taminiau J, Schabel E, Kleiner DE, Szitanyi P, Socha P, Schwimmer JB, Noviello S, Silberg DG, Torstenson R, Miller V, Lavine JE, Liver Forum Pediatric Working Group. Gastroenterology 2019; 157(6): 1448-1456 e1441.10.1053/j.gastro.2019.08.048.

Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum
Cheung A, Neuschwander-Tetri BA, Kleiner DE, Schabel E, Rinella M, Harrison S, Ratziu V, Sanyal AJ, Loomba R, Jeannin Megnien S, Torstenson R, Miller V, Liver Forum Case Definitions Working Group. Hepatology 2019; 70(5): 1841-1855.10.1002/hep.30672.

Challenges, Considerations, and Principles to Guide Trials of Combination Therapies for Chronic Hepatitis B Virus
Anderson RT, Lim SG, Mishra P, Josephson F, Donaldson E, Given B, Miller V. Gastroenterology 2019; 156(3): 529-533 e524.10.1053/j.gastro.2018.11.062.

2018

Use of Viral Load as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-analysis
Natori Y, Alghamdi A, Tazari M, Miller V, Husain S, Komatsu T, Griffiths P, Ljungman P, Orchanian-Cheff A, Kumar D, Humar A. Clin Infect Dis. 2018; 66(4): 617-631.10.1093/cid/cix793.

Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science
Siddiqui MS, Harrison SA, Abdelmalek MF, Anstee QM, Bedossa P, Castera L, Dimick-Santos L, Friedman SL, Greene K, Kleiner DE, Megnien S, Neuschwander-Tetri BA, Ratziu V, Schabel E, Miller V, Sanyal AJ, Liver Forum Case Definitions Working Group. Hepatology 2018; 67(5): 2001-2012.10.1002/hep.29607.

Definitions of Resistant and Refractory Cytomegalovirus Infection and Disease in Transplant Recipients for Use in Clinical Trials
Chemaly RF, Chou S, Einsele H, Griffiths P, Avery R, Razonable RR, Mullane KM, Kotton C, Lundgren J, Komatsu TE, Lischka P, Josephson F, Douglas CM, Umeh O, Miller V, Ljungman P, Resistant Definitions Working Group of the CMV Forum. Clin Infect Dis. 2019; 68(8): 1420-1426.10.1093/cid/ciy696

2017

Optimizing diagnosis of viraemic hepatitis C infection: the development of a target product profile
Ivanova Reipold E, Easterbrook P, Trianni A, Panneer N, Krakower D, Ongarello S, Roberts T, Miller V, Denkinger C. BMC Infect Dis. 2017; 17(Suppl 1): 707.10.1186/s12879-017-2770-5.

The HepTestContest: a global innovation contest to identify approaches to hepatitis B and C testing
Tucke JD, Meyers K, Best J, Kaplan K, Pendse R, Fenton KA, Andrieux-Meyer I, Figueroa C, Goicochea P, Gore C, Ishizaki A, Khwairakpam G, Miller V, Mozalevskis A, Ninburg M, Ocama P, Peeling R, Walsh N, Colombo MG, Easterbrook P. BMC Infect Dis. 2017; 17(Suppl 1): 701.10.1186/s12879-017-2771-4.

Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum
Patel YA, Imperial JC, Muir AJ, Anstee QM, DeBrota D, Dimick-Santos L, Filozof C, Mehta R, Sanyal AJ, Schabel E, Neuschwander-Tetri BA, Miller V, Liver Forum's Data Standardization Working Group. Gastroenterology 2017; 153(3): 621-625 e627.10.1053/j.gastro.2017.07.024.

Advancing the regulatory path on hepatitis B virus treatment and curative research: a stakeholders' consultation
Liu J, Goicochea P, Block T, Brosgart CL, Donaldson EF, Lenz E, Lim SG, Marins EG, Mishra P, Peters MG, Miller V. Journal of Virus Eradication 2017; 3:1-6.

Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials
Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, Pikis A, Razonable RR, Miller V, Griffiths PD. Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum. Clin Infect Dis. 2017; 64(1): 87-91.10.1093/cid/ciw668

2016

Human cytomegalovirus and transplantation: drug development and regulatory issues
McIntosh M, Hauschild B, Miller V. Journal of Virus Eradication 2016; 2:143-248

2015

Hepatitis C virus drug resistance-associated substitutions: State of the art summary
Lontok, E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, McPhee F, Mo H, Parkin N, Pilot-Matias T, Miller V. Hepatology 2015; 62(5): 1623-1632.10.1002/hep.27934

High-priority target product profile for hepatitis C diagnosis in decentralized settings: Report of a consensus meeting
Trianni A, Paneer N, and Denkinger C with input from other stakeholders on behalf of meeting participants. 22 April 2015, Vienna, Austria

2014

HIV and HCV Testing: HIV and hepatitis C virus infection in the United States: Whom and how to test
Panneer N, Lontok E, Branson BM, Teo C-G, Dan C, Parker M, Stekler JD, DeMaria A, Miller V. Clin Infect Dis. 2014; 59(6): 875-882.

Accelerating Drug Development Through Collaboration: The Hepatitis C Drug Development Advisory Group
Hutchison C, Kwong A, Ray S, Struble K, Swan T, Miller V. Clin Pharmacology & Therapeutics 2014; 96(2):153-55.

2013

The Untold Story of How High-Quality and Low-Cost Drugs Were Incorporated Into PEPFAR.
Quinones-Rivera A. HIV Forum Annals 15(1). (2013).

Closing in on the target: sustained virologic response in hepatitis C virus genotype 1 infection response-guided therapy
Lontok E, Mani N, Harrington PR, Miller V. Clin Infect Dis. 2013; 56(10): 1466-1470.10.1093/cid/cit025.

2012

Recommendations for standardized nomenclature and definitions of viral response in trials of HCV investigational agents
Wedemeyer H, Jensen DM, Dogofsky E, Mani N, Pawlotsky JM, Miller V. Hepatology 2012; 56:2398-2403.

Clinically relevant HCV drug resistance mutations
HCV Phenotype Working Group of the HCV Drug Development Advisory Group. HIV Forum Annals Volume 2012; 14 (2): 1-10.

Novel clinical trial designs for the development of new antiretroviral agents
Mani N, Murray J, Gulick RM, Josephson F, Miller V, Miele P, Strobos J, Struble K. AIDS 2012; 26:899-907.

Adverse Outcome Analyses of Observational Data: Assessing Cardiovascular Risk in HIV Disease
Triant V, Josephson F, Rochester CG, Althoff KN, Marcus K, Munk R, Cooper C, D'Agostino RB, Costagliola D, Sabin CA, Williams PL, Hughes S, Post WS, Chandra-Strobos N, Guaraldi G, Young SS, Obenchain R, Bedimo R, Miller V, Strobos J. Adverse outcome analyses of observational data: assessing cardiovascular risk in HIV disease. Clin Infect Dis. 2012; 54(3):408-13

2011

Safety considerations in the prevention of transmission of HIV by Pre-Exposure Prophylaxis (or “PrEP”)
Strobos J, Hauschild BC, Miller V. HIV Forum Annals 2011; 13(5): 1-11.

Municipal scale-up of HIV testing in the United States: Current status, challenges and opportunities from a multi-stakeholder perspective
Hauschild BC, Miller V, Strobos S. HIV Forum Annals 2011; 13(4): 1-8.

Recommendations from a Research Consultation to Inform the Next Generation of HIV Prevention Messaging for Men Who Have Sex with Men (MSM)
Uhrig J, Lewis MA, Ayala G, Stryker JE. HIV Forum Annals 2011; 13(3)

Global Pharmacovigilance for Antiretroviral Drugs: Overcoming Contrasting Priorities
Bakare N, Edwards IR, Stergachis A, Pal S, Holmes CB, Lindquist M, et al. PLoS Med 2011; 8(7): e1001054.Epub

Recognizing Leadership, Courage and Hands-On Engagement: Relearning Lessons 30 Years Later
Miller V. HIV Forum Annals 2011; 13(2)

Presentation of the C. Everett Koop HIV/AIDS Health Leadership Award to VADM C. Everett Koop, MD, SCD, 13th U.S. Surgeon General
Fauci A. HIV Forum Annals 2011; 13(2)

The Early Days of AIDS, As I Remember Them
Koop CE. HIV Forum Annals 201; 13(2)

Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: Recommendations from the HCV DRAG
Kwong A, Najera I, Bechtel J, Bowden S, Fitzgibbon J, Harrington P, Kempf D, Kieffer TL, Koletzki D, Kukolj G, Lim S, Pilot-Matias T, Lin K, Mani N, Mo H, O’Rear J, Otto M, Parkin N, Pawlotsky J-M, Petropoulos C, Picchio G, Raltston R, Reeves JD, Schooley RT, Seiwert S, Standring D, Stuyver L, Sullivan J, Miller V. Gastroenterology 2011; 140:755-760

HIV Clinic Capacity and Medical Workforce Challenges: Results of a Survey of Ryan White Part C-funded Programs
Hauschild B, Weddle A, Lubinski C, Tegelvik JK, Miller V, Saag M. HIV Forum Annals 2011; 13(1)

2010

2010 National Summit on HIV Diagnosis, Prevention and Access to Care.
HIV Forum Annals 2010; 12(1)

2009

The Forum for Collaborative HIV Research – a model for an integrated and inclusive approach to clinical research and drug development
Miller V. Clinical Pharmacology & Therapeutics 2009; 86:332-335

Evaluation of Impact of Adult Male Circumcision Programs on HIV Incidence and Prevalence: Current Research, Gaps in Knowledge and Recommendations for Additional Research
Kim S, Mischra S, Miller V. HIV Forum Annals
2009; 11(1): 1-13.

Metrics and Evaluation Measures for Monitoring the Implementation of Routine HIV Testing in the U.S.
Hauschild B, Onaga L. HIV Forum Annals
2009; 11(1)

2008

HIV Clinical Trial Design for Antiretroviral Development: Moving Forward
Chan-Tack KM, Struble KA, Morgensztejn N, Murray JS, Cheng B, Weller I, Miller V. AIDS. 2008; 22(18): 2419-2427.10.1097/QAD.0b013e32831692e6

Opt-Out Testing for Human Immunodeficiency Virus in the United States: Progress and Challenges
Bartlett JG, Branson BM, Fenton K, Hauschild BC, Miller V, Mayer KH. JAMA. 2008; 300:945-951

Initiatives for Developing and Comparing Genotype Interpretation Systems Step 1: External Validation of Existing Rules-Based Algorithm for Abacavir and ddI Evaluated on Virological Response
Assoumou L, Brun-V zinet F, Cozzi-Lepri A, Kuritzkes D, Phillips A, Zolopa A, DeGruttola V, Miller V, Costagliola D. J Infect Dis. 2008; 198:470-480.

Research Needs and Challenges in the Development of HIV Diagnostic and Treatment Monitoring Tests for Use in Resource-Limited Settings
Cheng B, Landay A, Miller V. Current Opinion in HIV AIDS 2008; 3:495-503.

Meeting the Demand for Male Circumcision
Bakare N, Miller V. HIV Forum Annals 2008; 10(1).

ARV Drugs, Adverse Events, Case Definition, Grading, Laboratory Diagnosis and Treatment Monitoring
Miller V. HIV Forum Annals
2008; 10(1).

2007

HIV-TB Co-Infection: Meeting the Challenge
Bakare N, Miller V. HIV Forum Annals 2007; 9(1).

Rethinking the Approach to Expanded Access Programs
Zechman E, Cheng B, Miller V. HIV Forum Annals 2007; 9(1).

Collaborative Approaches to HIV Drug Development: Planning for Long-Term Monitoring of Safety in CCR5 Antagonist Development
Fry J, Grossman JB, Miller V. HIV Forum Annals 2007; 9(1).

A New Era for HIV Prevention?
Collins C, Lyon M, Miller V. HIV Forum Annals 2007; 9(1).

HIV and TB in the Context of Universal Access: What is Working and What is not? Meeting Report
The World Health Organization forumresearch.org 2007.

2006

Buprenorphine and HIV Primary Care: New Opportunities for Integrated Treatment
Khalsa J, Vocci F, Altice F, Fiellin D, Miller V. CID 2006; 43:S169-S172.

Pediatric HIV Diagnosis & Laboratory Monitoring
Miller V. HIV Forum Annals 2006; 8(1).

Racial Ethnic Minority Issues in HIV/AIDS
Craig Hunter, Miller V. HIV Forum Annals 2006; 8(1).

HIV-1 Viral Load Assays for Resource-Limited Settings
Fiscus SA, Cheng B, Crowe SM, Demeter L, Jennings C, et al. PLOS Medicine 2006; 3:e417.

International Public Health Dialogue on HIV Testing and Counselling Report
Public Health Agency of Canada forumresearch.org 2006.

2005

Meeting Summary and Report: Developing and HIV Health Services Research Agenda
Jeffrey Levi, Miller V. HIV Forum Annals 2005; 7(1).

Antiretroviral Therapies for Treatment Experienced Patients: Current Status and Research Challenges
Struble KA, Murray JS, Cheng B, Gegeny T, Miller V, Gulick RM. AIDS 2005; 19:747-756.

Regulatory Considerations for the Treatment of Lipodystrophy
Snyder S, Cheng B, Miller V. HIV Forum Annals 2005; 7(1).

Buprenorphine and Primary HIV Care
Warden J, Hunter C, Miller V. HIV Forum Annals 2005; 7(1).

2004

Roundtable Report: Importance of Antiretroviral Drug Levels in Sanctuary Sites and Viral Reservoirs
Reddy YS, Kashuba A, Gerber J, Miller V. AIDS Research and Human Retroviruses 2003; 19:167-176.

2003

Quality of HIV Care - Closing the Gap: A Report on the Findings from the Quality of HIV Care Project
Miller V. HIV Forum Annals 2003; 6(1).

Monitoring of long-term toxicities of HIV treatments: an international perspective
Bisson G, Gross R, Evans S, Graham D, Lundgren J, Murray J, Arlett P, Pizzuti D, Primohamed M, Kerft-Jais C, Szarfman A, Justice A, Munk B, Carr A, Miller V, Weller I, Walker A. AIDS 2003; 17:2407-2417.

Protein Binding in Antiretroviral Therapies
Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, Gerber JG, Miller V on behalf of the Roundtable Participants. AIDS Research and Human Retroviruses 2003; 19:825-835.

QA/QC of CD4 and Viral Load Assays in the Resource-Limited Setting
Moody K, Miller V. HIV Forum Annals 2003; 6(1).

Cardiovascular Risk in HIV Infection and Treatment
Mascolini M, Miller V. HIV Forum Annals 2003; 6(1).

Forum for Collaborative HIV Research Summary of Executive Committee Retreat
Miller V. HIV Forum Annals 2003; 6(1).

STI Roundtable Discussion: Moving the Agenda Forward
Jefferys R, Miller V. HIV Forum Annals 2003; 6(1).

2002

What Defines HIV Lipodystrophy?
Mascolini M, Miller V. HIV Forum Annals 2002; 5(1).

Report of the Workshop: Sex and Gender Issues in HIV Disease
Miller V. HIV Forum Annals 2002; 5(1).

Cheaper HIV Drugs for Poor Nations Bring a New Challenge: Monitoring Treatment
Stephenson J. JAMA Jul. 10, 2002.

Transfer of HIV Diagnostic and Monitoring Technologies into Resource-Poor Settings
Le Transfert des Technologies pour le Diagnostic et le Monitoring de l'Infection VIH dans les Pays en Développement (French Version)
Mascolini M, Miller V. HIV Forum Annals 2002; 5(1).

Report from the 3rd International STI Workshop
Jefferys R, Miller V. HIV Forum Annals 2002; 5(1).

2001

Linkage and Integration of HIV Testing, Prevention, and Care
Palen J, Miller V. HIV Forum Annals 2001; 4(1).

Linking HIV Testing, Prevention and Care
Schietinger H. HIV Forum Annals 2001; 4(1).

Examining the Risk and Benefits of Directly Observed Therapy for Treatment of HIV Disease
Eddelman K. HIV Forum Annals 2001; 4(1).

Immunologic Markers to Evaluate Immune-Based Therapies in HIV Disease Meeting Reporting
Mascolini M. HIV Forum Annals 2001; 4(1).

Structured Treatment Interruptions Workshop Summary
Miller V. HIV Forum Annals 2001; 4(1).

Report of the DHHS Working Group on Dissemination of HIV Treatment Information
Miller V. HIV Forum Annals 2001; 4(1).

2000

Immune-Based Therapies: A Review of Clinical Endpoints Used in Trials of Selected Immunologic Agents
Eddleman K, Miller V. HIV Forum Annals 2000; 3(1).

Immune-Based Therapies and HIV Disease
Landay A, Bray J, Miller V. HIV Forum Annals 2000; 3(1).
HIV Forum Annals
Dec. 7, 2000

Bone Metabolism and HIV Disease Meeting Report
Raisz L, Aubin J, Miller V. HIV Forum Annals 2000; 3(1).

Mitochondrial Toxicity and HIV Disease Meeting Report
Brinkman K, Copeland W, Miller V. HIV Forum Annals 2000; 3(1).

Meeting on Drug Interaction Research in HIV Disease
Barr D, Miller V. HIV Forum Annals 2000; 3(1).

1999

Adherence to HIV Therapy: Building a Bridge to Success
DHHS Health Resources and Services Administration (HRSA) and The Forum for Collaborative HIV Research in collaboration with NIH Office of AIDS Research. forumresearch.org 1999.

Adherence to Highly Active Antiretroviral Therapy (HAART) Among Individuals
Barr D, Webster RD. forumresearch.org 1999.

The Potential of Patient Outcomes Research
Schietinger H. HIV Forum Annals 1999; 2(1).

Simplifying Antiretroviral Treatment Regimens-A Summary of Current Research
Gilden D. forumresearch.org 1999

Failure of Initial Antiretroviral Treatment Regimens
Gilden D. HIV Forum Annals 1999; 2(1).

The Challenges of Clinical Trial Design in Assessing the Effects of Anti-HIV Therapy in Heavily Pre-Treated Patients
Barr D. HIV Forum Annals 1999; 2(1).